alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Eye Institute Special Emphasis Panel, NEI K99 Grant Applications.                    

*Date:*                         March 1, 2010.                    

*Time:*                         8:30 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                     

*Place:*                         Embassy Suites Hotel—Chevy Chase Pavilion Washington, DC 20015.                    

*Contact Person:*                         Daniel R. Kenshalo, PhD, Scientific Review Officer, National Eye Institute, National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892, 301-451-2020,                         *kenshalod@nei.nih.gov*.                    

This Notice is late due to administrative procedures.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: February 17 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-3784 Filed 2-25-10; 8:45 am]

BILLING CODE 4140-01-M
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-START>                             JUL-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                             236
<SECURITIES>                                         0
<RECEIVABLES>                                    2,562
<ALLOWANCES>                                     1,606
<INVENTORY>                                      1,212
<CURRENT-ASSETS>                                 3,332
<PP&E>                                           3,578
<DEPRECIATION>                                   3,195
<TOTAL-ASSETS>                                   6,624
<CURRENT-LIABILITIES>                           12,270
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             6
<OTHER-SE>                                     (5,646)
<TOTAL-LIABILITY-AND-EQUITY>                     6,624
<SALES>                                          1,316
<TOTAL-REVENUES>                                 1,904
<CGS>                                            1,199
<TOTAL-COSTS>                                    1,869
<OTHER-EXPENSES>                                 3,408
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 317
<INCOME-PRETAX>                                (3,156)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (3,156)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,156)
<EPS-BASIC>                                      (.56)
<EPS-DILUTED>                                    (.56)


</TABLE>
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.56 Review of ongoing investigations. ( a ) The sponsor shall monitor the progress of all clinical investigations being conducted under its IND.
( b ) A sponsor who discovers that an investigator is not complying with the signed agreement (Form FDA-1572), the general investigational plan, or the requirements of this part or other applicable parts shall promptly either secure compliance or discontinue shipments of the investigational new drug to the investigator and end the investigator's participation in the investigation. If the investigator's participation in the investigation is ended, the sponsor shall require that the investigator dispose of or return the investigational drug in accordance with the requirements of § 312.59 and shall notify FDA.
( c ) The sponsor shall review and evaluate the evidence relating to the safety and effectiveness of the drug as it is obtained from the investigator. The sponsors shall make such reports to FDA regarding information relevant to the safety of the drug as are required under § 312.32. The sponsor shall make annual reports on the progress of the investigation in accordance with § 312.33.
( d ) A sponsor who determines that its investigational drug presents an unreasonable and significant risk to subjects shall discontinue those investigations that present the risk, notify FDA, all institutional review boards, and all investigators who have at any time participated in the investigation of the discontinuance, assure the disposition of all stocks of the drug outstanding as required by § 312.59, and furnish FDA with a full report of the sponsor's actions. The sponsor shall discontinue the investigation as soon as possible, and in no event later than 5 working days after making the determination that the investigation should be discontinued. Upon request, FDA will confer with a sponsor on the need to discontinue an investigation.
[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 67 FR 9586, Mar. 4, 2002]
§ 182.8985 Zinc chloride. ( a ) *Product.* Zinc chloride.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



     In connection with the Quarterly  Report of Tonga Capital  Corporation (the
"Company") on Form 10-QSB for the period ending March 31, 2006 as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report").  I,
Jeffrey  Ploen,  Chief  Executive  Officer  and Chief  Financial  Officer of the
company,  certify,  pursuant  to 18 USC  Section  1350,  as adopted  pursuant to
Section 906 of the  Sarbanes-Oxley Act of 2002, that to the best of my knowledge
and belief.

        (1)     The Report fully complies with the requirements of Section 13(a)
                or 15(d) of the Securities Exchange Act of 1934; and

        (2)     The information contained in the Report fairly presents, in all
                material respects, the financial condition and results of
                operations of the Company.




                                         /s/ Jeffrey Ploen
                                         --------------------------------
                                         Jeffrey Ploen, CEO/CFO
Dated: May 19, 2006
§ 310.533 Drug products containing active ingredients offered over-the-counter (OTC) for human use as an anticholinergic in cough-cold drug products. ( a ) Atropine sulfate, belladonna alkaloids, and belladonna alkaloids as contained in Atropa belladonna and Datura stramonium have been present as ingredients in cough-cold drug products for use as an anticholinergic. Anticholinergic drugs have been marketed OTC in cough-cold drug products to relieve excessive secretions of the nose and eyes, symptoms that are commonly associated with hay fever, allergy, rhinitis, and the common cold. Atropine sulfate for oral use as an anticholinergic is probably safe at dosages that have been used in marketed cough-cold products (0.2 to 0.3 milligram); however, there are inadequate data to establish general recognition of the effectiveness of this ingredient. The belladonna alkaloids, which contain atropine (*d, dl* hyoscyamine) and scopolamine (*l-* hyoscine), are probably safe for oral use at dosages that have been used in marketed cough-cold products (0.2 milligram) but there are inadequate data to establish general recognition of the effectiveness of these ingredients as an anticholinergic for cough-cold use. Belladonna alkaloids for inhalation use, as contained in Atropa belladonna and Datura stramonium, are neither safe nor effective as an OTC anticholinergic. There are inadequate safety and effectiveness data to establish general recognition of the safety and/or effectiveness or any of these ingredients, or any other ingredient, for OTC use as an anticholinergic in cough-cold drug products.
( b ) Any OTC cough-cold drug product that is labeled, represented, or promoted for use as an anticholinergic is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act, for which an approved new drug application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any cough-cold drug product labeled, represented, or promoted for OTC use as an anticholinergic is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.
( d ) After the effective date of the final regulation, any such OTC cough-cold drug product that is labeled, represented, or promoted for use as an anticholinergic may not be initially introduced or initially delivered for introduction into interstate commerce unless it is the subject of an approved new drug application.
[50 FR 46587, Nov. 8, 1985, as amended at 55 FR 11579, Mar. 29, 1990]
###### Editorial Note on Part 369

#### Editorial Note:

Nomenclature changes to part 369 appear at 69 FR 13717, Mar. 24, 2004.

#### § 369.1 Purpose of issuance.

The warning and caution statements suggested in subparts B and C of this part, for inclusion in the label or labeling of drugs and devices subject to section 502(d) and (f)(2) and other relevant provisions of the Federal Food, Drug, and Cosmetic Act are issued for the purpose of assisting industry in preparing proper labeling for these articles for over-the-counter sale and in meeting the legal requirements of the act that the label or labeling of drugs and devices bear adequate warnings, in such manner and form as are necessary for the protection of users. Only section 502(d) of the act requires use of the specific language included in these suggested warning and caution statements. These suggested warning or caution statements are illustrative of those that may be necessary or desirable. It is the responsibility of the manufacturer, packer, shipper, or distributor in interstate commerce to see that such statements are adequate for compliance with the provisions of the law. Omission of any article from this suggested list does not relieve drugs and devices subject to provisions of the act from bearing adequate warning or caution statements where such statements are necessary or desirable for the protection of the user.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                       1,574,280
<SECURITIES>                                         0
<RECEIVABLES>                                  375,714
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      27,416,496
<DEPRECIATION>                              13,879,759
<TOTAL-ASSETS>                              35,846,416
<CURRENT-LIABILITIES>                       43,751,305
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                 (7,904,889)
<TOTAL-LIABILITY-AND-EQUITY>                35,846,416
<SALES>                                      4,083,276
<TOTAL-REVENUES>                             4,083,276
<CGS>                                                0
<TOTAL-COSTS>                                3,687,389
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             902,631
<INCOME-PRETAX>                              (505,791)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (505,791)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
§ 332.31 Professional labeling. ( a ) The labeling of the product provided to health professionals (but not to the general public) may contain as additional indications postoperative gas pain or for use in endoscopic examination.
( b ) Professional labeling for an antiflatulent-antacid combination may contain information allowed for health professionals for antacids and antiflatulents.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1923 Urea. ( a ) Urea (CO(NH2)2, CAS Reg. No. 57-13-6) is the diamide of carbonic acid and is also known as carbamide. It is a white, odorless solid and is commonly produced from CO2 by ammonolysis or from cyanamide by hydrolysis.
( b ) The ingredient must be of a purity suitable for its intended use.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a formulation aid as defined in § 170.3(o)(14) of this chapter and as a fermentation aid.
( 2 ) The ingredient is used in yeast-raised bakery products; in alcoholic beverages as defined in § 170.3(n)(2) of this chapter; and in gelatin products.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 51616, Nov. 10, 1983, as amended at 49 FR 19816, May 10, 1984; 73 FR 8608, Feb. 14, 2008]
Editorial Note on Part 173
Editorial Note: Nomenclature changes to part 173 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; and 81 FR 49896, July 29, 2016.

§ 173.342 Chlorofluorocarbon 113 and perfluorohexane. A mixture of 99 percent chlorofluorocarbon 113 (1,1,2-trichloro-1,2,2-trifluoroethane) (CAS Reg. No. 76-13-1, also known as fluorocarbon 113, CFC 113 and FC 113) and 1 percent perfluorohexane (CAS Reg. No. 355-42-0) may be safely used in accordance with the following prescribed conditions: ( a ) The additive chlorofluorocarbon 113 has a purity of not less than 99.99 percent.
( b ) The additive mixture is intended for use to quickly cool or crust-freeze chickens sealed in intact bags composed of substances regulated in parts 174, 175, 177, 178, and § 179.45 of this chapter and conforming to any limitations or specifications in such regulations.
[55 FR 8913, Mar. 9, 1990]
IN THE SUPREME COURT OF THE STATE OF NEVADA

CARL DEAN EDWARDS, Petitioner, vs. THE STATE OF NEVADA, Respondent. No. 69746 

# FILED MAR 17 2016

ORDER DENYING PETITION This is a pro se petition for extraordinary relief. Petitioner challenges the validity of his judgment of conviction and sentence. We have reviewed the documents submitted in this matter, and without deciding upon the merits of any claims raised therein, we decline to exercise original jurisdiction in this matter. A challenge to the validity of the judgment of conviction must be raised in a postconviction petition for a writ of habeas corpus filed in the district court in the first instance.' NRS 34.724(2)(b); NRS 34.738(1). Accordingly, we

ORDER the petition DENIED.

J.

Hardesty
, J. Saitta

'We express no opinion as to whether petitioner could meet the procedural requirements of NRS chapter 34.

SUPREME COURT OF NEVADA (0) 1947 A '40° 

# _Na l()cc: Carl Dean Edwards Attorney General/Carson City Clark County District Attorney Eighth District Court Clerk

SUPREME COURT

OF NEVADA 2 (0) 1947A
#### § 225.135 Work and storage areas.

Work areas and equipment used for the production or storage of medicated feeds or components thereof shall not be used for, and shall be physically separated from, work areas and equipment used for the manufacture and storage of fertilizers, herbicides, insecticides, fungicides, rodenticides, and other pesticides unless such articles are approved or index listed for use in the manufacture of animal feed.

[72 FR 69120, Dec. 6, 2007]
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

REGION VII
901 NORTH 5TH STREET KANSAS CITY, KANSAS 66101

September 23, 2011

Lawrence E Copeland Jr

P O Box 4011 Mcchord Afb, Washington 98438

RE: SAID: 548
2416 Binney Street
Lead-Based Paint (LBP) Assessment

Dear Owner/Resident:

A Lead Based Paint assessment was recently performed on your property by the U.S. Environmental Protection Agency as part of the Omaha Lead site investigation. The purpose of this assessment is to determine whether a significant quantity of LBP is present on the exterior surface of structures, where deteriorating paint conditions (peeling, flaking, cracking, etc) exist that might increase lead concentrations in the yard above acceptable levels.

Enclosed are the LBP assessment sheets for 2416 Binney Street. The EPA has developed paint stabilization eligibility criteria that involve measuring the amount of deteriorated LBP on a structure and calculating the concentration of lead in soils around the home that would result if all of the identified deteriorated paint were to fall to the ground and uniformly mix with the soil under certain assumptions. During the LBP assessment, the areal extent of the deteriorated paint observed on structure surfaces was estimated and the lead content in the deteriorated paint was measured using an X-Ray Fluorescence instrument.

The data obtained during the LBP assessment was used to estimate the increase in soil lead concentration that would result if all of the deteriorating paint identified in the assessment were to fall to the ground and mix with surface soil within six feet of the foundation of the structure. For purposes of this calculation, the deteriorating LBP on a structure is assumed to fall onto the ground surface within six feet of the foundation and be uniformly mixed with the top one inch of soil. The estimated lead concentration in the soil potentially caused by the deteriorating LBP provides a measure of the severity of LBP deterioration on individual structures. The EPA uses these criteria to rank properties based on the potential for recontamination of soil to occur. Paint stabilization is being offered at only those households with the most severe LBP problems, particularly where children under the age of seven reside.

The LBP assessment performed by the EPA using the above criteria indicated that your house IS NOT eligible for paint stabilization.If you have any questions or concerns, please contact the EPA Public Information Center at (402) 731-3045.

Sincerely,

Pauletta R. France-Isetts Project Coordinator Environmental Protection Agency

Enclosures
Para información en español, llame al EPA Information Center (402) 731-3045.- - - - -- Omaha Lead Site ~orth Arrow
Address:2416 BINNEY ST Site Sketch

LBP Assessment

ALT 

# 1

Plan View

- Indicate number of stories and perimeter dimensions of structure Indicate regions of deterioration and describe

(Deterlorat~an could include surfaces that are worn due to fridon checkmg, crackmg and flakmg all~gatormg, bl~stenng andior peelmg) 

# "- Phone:-
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               JUN-30-1997
<EXCHANGE-RATE>                                      1
<CASH>                                       1,154,743
<SECURITIES>                                         0
<RECEIVABLES>                                  411,415
<ALLOWANCES>                                         0
<INVENTORY>                                    460,573
<CURRENT-ASSETS>                             2,079,140
<PP&E>                                          64,608
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               2,149,558
<CURRENT-LIABILITIES>                          173,383
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     1,976,175
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 2,149,558
<SALES>                                      1,145,214
<TOTAL-REVENUES>                             1,145,214
<CGS>                                          568,363
<TOTAL-COSTS>                                  568,363
<OTHER-EXPENSES>                               347,123
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                249,782
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            249,782
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   249,782
<EPS-PRIMARY>                                      .07
<EPS-DILUTED>                                      .07
        

</TABLE>